Magali Taiel

GenSight Biologics (France) — France

Biochemistry, Genetics and Molecular Biology · Life Sciences

15h-index1.9kcitations47works1.92yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Retinal Development and Disorders(36), Mitochondrial Function and Pathology(18), Retinal Diseases and Treatments(13), Photosynthetic Processes and Mechanisms(8), Ocular Diseases and Behçet’s Syndrome(6)

Publications47 total

Rasch analysis of the NEI-VFQ-25: vision-related quality of life in Leber hereditary optic neuropathy after lenadogene nolparvovec gene therapy
BMJ Open Ophthalmology·2025· 1 citedOpen Access
Predictors of Final Visual Outcome in Patients With Leber Hereditary Optic Neuropathy Treated With Lenadogene Nolparvovec Gene Therapy
Investigative Ophthalmology & Visual Science·2025· 1 citedOpen Access
The Latest Data from Lenadogene Nolparvovec Gene Therapy Trials for Leber Hereditary Optic Neuropathy (S14.001)
Neurology·2025
Ocular Post-mortem Analyses with Histopathological and Molecular Assessments in Leber Hereditary Optic Neuropathy Following AAV2 Gene Therapy (P5-11.025)
Neurology·2025· 1 cited
Ocular post‐mortem analyses with histopathological and molecular assessments in leber hereditary optic neuropathy following AAV2 gene therapy
Acta Ophthalmologica·2025
Long‐term results of unilateral or bilateral injection of lenadogene nolparvovec gene therapy for leber hereditary optic neuropathy
Acta Ophthalmologica·2025· 1 cited
Meta‐analysis of treatment outcomes for patients with m.117 | 8G>A MT‐ND4 leber hereditary optic neuropathy
Acta Ophthalmologica·2025
Predictive factors of final visual outcome in patients with leber hereditary optic neuropathy treated with lenadogene nolparvovec gene therapy
Acta Ophthalmologica·2025
Long‐term results of unilateral or bilateral injection of lenadogene nolparvovec gene therapy for leber hereditary optic neuropathy
Acta Ophthalmologica·2025
Efficacy and safety of lenadogene nolparvovec gene therapy for leber hereditary optic neuropathy in the real‐life setting
Acta Ophthalmologica·2025
Predictive factors of final visual outcome in patients with leber hereditary optic neuropathy treated with lenadogene nolparvovec gene therapy
Acta Ophthalmologica·2025
Five-Year Outcomes of Lenadogene Nolparvovec Gene Therapy in Leber Hereditary Optic Neuropathy
JAMA Ophthalmology·2024· 12 citedOpen Access
Meta-analysis of treatment outcomes for patients with m.11778G>A MT-ND4 Leber hereditary optic neuropathy
Survey of Ophthalmology·2024· 11 citedOpen Access
Retinal damage promotes mitochondrial transfer in the visual system of a mouse model of Leber hereditary optic neuropathy
Neurobiology of Disease·2024· 2 citedOpen Access
Treatment Options for Acute/Subacute Patients with m.11778G>A MT-ND4 Leber Hereditary Optic Neuropathy: A Meta-analysis (P10-10.006)
Neurology·2024
Indirect Comparison of Lenadogene Nolparvovec Gene Therapy versus Natural History in m.11778G>A MT-ND4 Leber Hereditary Optic Neuropathy Patients (S12.005)
Neurology·2023· 1 cited
Long-term Follow-up of m.11778G>A MT-ND4-LHON Patients Treated with Lenadogene Nolparvovec Ocular Gene Therapy: the RESTORE Study (S12.004)
Neurology·2023· 1 cited
Ocular stress enhances contralateral transfer of lenadogene nolparvovec gene therapy through astrocyte networks
Molecular Therapy·2023· 13 citedOpen Access
Safety of Lenadogene Nolparvovec Gene Therapy Over 5 Years in 189 Patients With Leber Hereditary Optic Neuropathy
American Journal of Ophthalmology·2022· 22 citedOpen Access
The phase 3 <scp>REFLECT</scp> trial: Efficacy and safety of bilateral gene therapy for Leber hereditary optic neuropathy (<scp>LHON</scp>)
Acta Ophthalmologica·2022· 1 cited
page 1 of 3Next →

Frequent Co-authors

José‐Alain Sahel(40), Patrick Yu‐Wai‐Man(37), Valério Carelli(37), Valérie Biousse(33), Nancy J. Newman(30), Mark L. Moster(26), Alfredo A. Sadun(26), Robert C. Sergott(25), Catherine Vignal(22), Laure Blouin(16), Thomas Klopstock(16), Bart P. Leroy(12), Sean P. Donahue(12), Chiara La Morgia(11), Prem S. Subramanian(11), Catherine Vignal‐Clermont(11), Rustum Karanjia(9), Adam A. DeBusk(9), Bart K. Chwalisz(9), An-Guor Wang(8)